Abstract
α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Graphical Abstract
Current Bioactive Compounds
Title:Antiedematogenic Effect of α-Phellandrene in Animal Models
Volume: 12 Issue: 2
Author(s): Hálmisson D.S. Siqueira, Benedito P.S. Neto, Damião P. Sousa, Bruno S. Gomes, Francisco V.M. Cunha and Francisco A. Oliveira
Affiliation:
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Abstract: α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Export Options
About this article
Cite this article as:
D.S. Siqueira Hálmisson, P.S. Neto Benedito, P. Sousa Damião, S. Gomes Bruno, V.M. Cunha Francisco and A. Oliveira Francisco, Antiedematogenic Effect of α-Phellandrene in Animal Models, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/1573407212666160210231052
DOI https://dx.doi.org/10.2174/1573407212666160210231052 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry The Emerging Role of the Histamine H4 Receptor in Anti-inflammatory Therapy
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery An Interplay between Obesity and Inflammation in Gestational Diabetes Mellitus
Current Pharmaceutical Biotechnology Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Ocular Application of Macrobiomolecules in Anti-Allergy and Anti- Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Stopping Cancer in its Tracks: Using Small Molecular Inhibitors to Target Glioblastoma Migrating Cells
Current Drug Discovery Technologies Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia
Current Cancer Drug Targets The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Pathobiology of Chronic Inflammatory Skin Diseases: Interplay Between Keratinocytes and Immune Cells as a Target for Anti-Inflammatory Drugs
Current Drug Metabolism Exocrine Pancreas Involvement in Celiac Disease: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science The Effect of Tranexamic Acid on Preventing Post-partum Hemorrhage Due to Uterine Atony: A Triple-blind Randomized Clinical Trial
Current Clinical Pharmacology Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Novel Hybrid Compound 4-[(E)-2-phenylethenesulfonamido]-N-hydroxybutanamide with Antimetastatic and Cytotoxic Action: Synthesis and Anticancer Screening
Anti-Cancer Agents in Medicinal Chemistry Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design